Takeda aims at Bristol and Merck
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
Vincerx stalls again
The group reports responses with its CD123-targeting ADC, but cash is running short.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
EHA 2024 – Shattuck reassurances fall on deaf ears
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
